160 related articles for article (PubMed ID: 2826175)
21. Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.
Ukai M; Kameyama T
Brain Res; 1985 Jul; 337(2):352-6. PubMed ID: 2992682
[TBL] [Abstract][Full Text] [Related]
22. Effect of the kappa-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task.
Ohno M; Yamamoto T; Ueki S
Eur J Pharmacol; 1991 Feb; 193(3):357-61. PubMed ID: 1647321
[TBL] [Abstract][Full Text] [Related]
23. [Central depressor effect of U50488H: a highly selective kappa opioid agonist].
Feng Y; Han JS
Sheng Li Xue Bao; 1987 Jun; 39(3):305-9. PubMed ID: 2823391
[No Abstract] [Full Text] [Related]
24. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H.
Ho BY; Takemori AE
J Pharmacol Exp Ther; 1989 Aug; 250(2):508-14. PubMed ID: 2547935
[TBL] [Abstract][Full Text] [Related]
25. The effect of U-50,488H, a kappa-opiate receptor agonist on tolerance to the analgesic and hyperthermic effects of morphine in the rat.
Bhargava HN; Matwyshyn G; Ramarao P
Gen Pharmacol; 1991; 22(3):429-34. PubMed ID: 1651266
[TBL] [Abstract][Full Text] [Related]
26. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
Wilson JL; Nayanar V; Walker JS
Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
[TBL] [Abstract][Full Text] [Related]
27. Effects of acute and chronic administration of dizocilpine on the pharmacological responses to U-50,488H and brain and spinal cord kappa-opioid receptors in the rat.
Bhargava HN; Matwyshyn GA; Gudehithlu KP
Pharmacology; 1995 Nov; 51(5):323-30. PubMed ID: 8584584
[TBL] [Abstract][Full Text] [Related]
28. Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex inrat.
Diop L; Rivière PJ; Pascaud X; Junien JL
Eur J Pharmacol; 1994 Dec; 271(1):65-71. PubMed ID: 7698213
[TBL] [Abstract][Full Text] [Related]
29. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
[TBL] [Abstract][Full Text] [Related]
30. Involvement of dynorphin and the kappa opioid receptor in feeding.
Morley JE; Levine AS
Peptides; 1983; 4(6):797-800. PubMed ID: 6143298
[TBL] [Abstract][Full Text] [Related]
31. The kappa-opioid U-50,488H suppresses the initiation of nocturnal spontaneous drinking in normally hydrated rats.
Badiani A; Stewart J
Psychopharmacology (Berl); 1992; 106(4):463-73. PubMed ID: 1315973
[TBL] [Abstract][Full Text] [Related]
32. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
33. Binding characteristics of [3H]SCH 23390 in spinal cord and discrete brain regions of kappa-opiate tolerant-dependent and abstinent rats.
Bhargava HN; Gulati A; Ramarao P
Pharmacology; 1991; 42(3):121-7. PubMed ID: 1647533
[TBL] [Abstract][Full Text] [Related]
34. Kappa opioid receptor-mediated depression of activity evoked in convergent dorsal horn cells by thermal and non-thermal noxious stimulation.
Hernández A; Paeile C; Pérez H; Pelissier T; Soto-Moyano R
Eur J Pharmacol; 1990 Sep; 186(2-3):323-5. PubMed ID: 1963150
[TBL] [Abstract][Full Text] [Related]
35. Effects of a kappa-receptor agonist, U-50,488H, on the release of endogenous brain dopamine.
Clow DW; Jhamandas K
Can J Physiol Pharmacol; 1988 Feb; 66(2):128-33. PubMed ID: 2836044
[TBL] [Abstract][Full Text] [Related]
36. Majonoside-R2, a major constituent of Vietnamese ginseng, attenuates opioid-induced antinociception.
Huong NT; Matsumoto K; Yamasaki K; Duc NM; Nham NT; Watanabe H
Pharmacol Biochem Behav; 1997; 57(1-2):285-91. PubMed ID: 9164584
[TBL] [Abstract][Full Text] [Related]
37. Hyperalgesic effect of the selective kappa opioid agonist, U-50488H in mice.
Ramabadran K
Jpn J Pharmacol; 1983 Dec; 33(6):1289-92. PubMed ID: 6321836
[No Abstract] [Full Text] [Related]
38. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice.
Roerig SC; Fujimoto JM
J Pharmacol Exp Ther; 1989 Jun; 249(3):762-8. PubMed ID: 2567350
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of two kappa-opiate agonists, U-50,488H and U-69,593, on the binding of 3H-(3-MeHis2) thyrotropin-releasing hormone to rat spinal cord and amygdala membranes.
Rahmani NH; Gulati A; Bhargava HN
Pharmacology; 1991; 43(3):156-62. PubMed ID: 1663623
[TBL] [Abstract][Full Text] [Related]
40. Chronic selective blockade of mu opioid receptors produces analgesia and augmentation of the effects of a kappa agonist.
Walker MJ; Lê AD; Poulos CX; Cappell H
Brain Res; 1991 Jan; 538(2):181-6. PubMed ID: 1849435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
